Barbara J. Klencke M.D.
Net Worth
Last updated:
What is Barbara J. Klencke M.D. net worth?
The estimated net worth of Dr. Barbara J. Klencke M.D. is at least $4,512,450 as of 18 Aug 2020. He owns shares worth $274,950 as insider and has received compensation worth at least $4,237,500 in Sierra Oncology, Inc..
What is the salary of Barbara J. Klencke M.D.?
Dr. Barbara J. Klencke M.D. salary is $706,250 per year as Chief Medical Officer in Sierra Oncology, Inc..
How old is Barbara J. Klencke M.D.?
Dr. Barbara J. Klencke M.D. is 68 years old, born in 1957.
What stocks does Barbara J. Klencke M.D. currently own?
As insider, Dr. Barbara J. Klencke M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Sierra Oncology, Inc. (SRRA) | Chief Medical Officer | 5,000 | $54.99 | $274,950 |
What does Sierra Oncology, Inc. do?
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
Barbara J. Klencke M.D. insider trading
Sierra Oncology key executives
Sierra Oncology, Inc. executives and other stock owners filed with the SEC:
- Dr. Barbara J. Klencke M.D. (68) Chief Medical Officer
- Dr. Mark M. Kowalski M.D., Ph.D. (70) Chief of Research & Early Devel.
- Dr. Stephen George Dilly M.B.B.S, Ph.D. (65) Pres, Chief Executive Officer & Director